Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.81 |
| ▸ | TNF | P01375 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.81 |
| ▸ | ACHE | P22303 | 2/20 | 0.81 |
| ▸ | PDE4A | P27815 | 2/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.81 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10522005 | 0.99 | ADORA2B (0.79) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| 1-[4-Carboxypropyl]-3,7-Dimethylxanthine SCHEMBL5420399 | 0.96 | ADORA2B (0.74) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8570022 | 0.91 | ADORA2B (0.77) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| Pentoxifylline SCHEMBL3986204 | 0.90 | ADORA2B (1.00) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| Pentoxifylline SCHEMBL34039 | 0.90 | ADORA2B (1.00) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL18255987 | 0.90 | ADORA2B (0.81) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| Bisdionin D SCHEMBL16120988 | 0.89 | ADORA2B (0.79) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL9123538 | 0.88 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL8150960 | 0.88 | ADORA2B (0.97) | ADORA2BTNFLMNACYP1A2NFKB1 | |
| SCHEMBL9123779 | 0.88 | ADORA2B (0.79) | ADORA2BTNFLMNACYP1A2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0956855-B1 | Immunosuppressive effects of 8 substituted xanthine derivatives | LEUVEN K U RES & DEV (BE) | 2003-03-12 | — | — | EP | claimed |
| EP-0956855-A1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. Leuven Research & Development (BE) | 1999-11-17 | — | — | EP | claimed |
| EP-0484785-B1 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST ROUSSEL PHARMA (US) | 1996-05-22 | — | — | EP | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-9725404-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725404-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | ALAPATI MOHAN MURALI (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | ALAPATI MOHAN MURALI (IN) | 2017-05-11 | — | — | US | disclosed |
| EP-2265612-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| US-20140121226-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2013013052-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20090239886-A1 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239886-A1 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7253176-B1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-07 | — | — | US | disclosed |
| US-6420374-B1 | PENTOXIFYLLINE. | FRED HUTCHINSON CANCER RESEARCH CENTER | 2002-07-16 | — | — | US | disclosed |
| EP-0493682-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0490181-A1 | Use of xanthines for preparation of a medicament having immunosuppressing activity | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-17 | — | — | EP | disclosed |
| EP-0484785-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | ADORA2B 3096/4885TNF 1450/4885LMNA 950/4885 |
| US-20170129870-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SLC5A1, SLC6A4, SLC6A2 | ADORA2B 412/4885TNF 737/4885LMNA 1437/4885 |
| US-20090239886-A1 | Substituted xanthine derivatives | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885LMNA 2823/4885 |
| US-20140121226-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, CXCR4, CXCR3 | ADORA2B 24/4885TNF 1024/4885LMNA 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.